Tarsus Pharmaceuticals, Inc. reports developments tied to its commercial eye-care franchise and biopharmaceutical pipeline. Company news commonly covers XDEMVY, its lotilaner ophthalmic solution marketed in the U.S. for Demodex blepharitis, including product-sales updates, prescribing trends, conference presentations, and international regulatory milestones for TP-03 through its Greater China partner.
Updates also address pipeline programs such as TP-04 for ocular rosacea and TP-05, an investigational oral lotilaner tablet being studied for Lyme disease prevention. Recurring corporate items include quarterly and annual financial results, investor-conference participation, board and governance changes, and business updates related to Tarsus' ophthalmology-focused commercialization strategy.
Tarsus Pharmaceuticals (NASDAQ: TARS) management plans to attend three upcoming investor conferences, including fireside chats at Guggenheim and Piper Sandler.
The Guggenheim chat is November 10 at 12:30 p.m. PT; Jefferies attendance is November 18–19; and the Piper Sandler chat is December 1 at 11:30 a.m. PT. Live webcasts and additional information will be available on the company website, with replays available within 48 hours for a limited time.
Tarsus Pharmaceuticals (NASDAQ: TARS) reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64% year over year. Gross margin remained approximately 93%. Net loss widened to $668.3 million, or $14.40 per share, from $12.6 million, or $0.30 per share, a year earlier. Results included $632.2 million of acquired research and development expenses following the completed iRenix Medical and Alkeus Pharmaceuticals acquisitions.
Nine-month product sales reached $513.9 million versus $299.7 million; net loss was $693.9 million versus $58.0 million. Cash, cash equivalents and marketable securities totaled $309.6 million at September 30. Tarsus expects TP-04 and TP-05 Phase 2 results in the first half of 2027. It plans to start the IRX-101 Phase 3 study in that period, with results expected in 2028; gildeuretinol Phase 3 results are expected in 2029. Neera Clase was appointed Chief Commercial Officer.
Tarsus Pharmaceuticals (TARS) will report its third quarter 2026 financial results and provide a corporate update on November 3, 2026. The live webcast will begin at 1:30 p.m. PT / 4:30 p.m. ET. A recording will be available on the company website shortly afterward and archived for approximately 90 days.
Tarsus Pharmaceuticals (Nasdaq: TARS) appointed Neera Clase as Chief Commercial Officer, effective November 1, 2026, following her interim service.
Clase has held the interim role since July 2026 and previously served as Senior Vice President of Market Access. She will lead commercial strategy and execution, focusing on expanding XDEMVY’s reach among eye care professionals and patients. Clase believes XDEMVY has the potential to exceed $2 billion in peak sales. Her responsibilities also include commercial planning for Phase 3 programs gildeuretinol for Stargardt disease and IRX-101 as an ocular antiseptic, plus Phase 2 programs TP-04 for ocular rosacea and TP-05 for Lyme disease prevention.
Lisata Therapeutics (Nasdaq: LSTA) appointed Jeffrey Farrow to its Board of Directors as a Class III director, effective October 13, 2026. Farrow fills a newly created seat, expanding the Board from seven to eight members, and will serve on the Audit Committee. The Board determined that he is independent under Nasdaq listing rules.
Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, roles he has held since April 2023. He also serves on the boards of Clover Biopharmaceuticals and Achieve Life Sciences.
Tarsus Pharmaceuticals (TARS) plans to present 11 scientific abstracts at the American Academy of Optometry meeting from September 30 to October 3.
The abstracts cover Demodex blepharitis, ocular rosacea and real-world experience with XDEMVY. Ten are scheduled as posters on October 1, and one as a paper on October 2. The announcement lists presentation topics but does not report findings from the abstracts.
Tarsus Pharmaceuticals (TARS) has completed its previously announced acquisition of Alkeus Pharmaceuticals, a privately held biotechnology company focused on retinal diseases.
With the closing, Tarsus gains worldwide rights to gildeuretinol (ALK-001), a differentiated, late-stage, oral investigational medicine designed to reduce toxic dimer accumulation while preserving the normal visual cycle in Stargardt disease. Tarsus states that ALK-001 could be a potential blockbuster in one of the largest inherited retinal diseases and is highly complementary to its eye care focus.
ALK-001 has received Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations from the U.S. FDA for Stargardt disease and is being evaluated in the global NORTHSTAR Phase 3 trial, with topline data anticipated in 2029. The transaction closed after satisfaction of customary conditions under the definitive merger agreement.
Tarsus (NASDAQ:TARS) announced that management will attend two investor events: the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, and the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, which will include a fireside chat at 6:00 a.m. PT / 9:00 a.m. ET. Live webcasts, replays, and additional details will be available in the events section of the Tarsus website, with replays posted within 48 hours and archived for a limited time.
Tarsus (NASDAQ:TARS) reported second quarter 2026 net product sales of $173.9 million for XDEMVY, up more than 69% year-over-year, and raised full-year 2026 XDEMVY net product sales guidance to $685–$705 million. Gross margin remained high at 93%.
The company reported a Q2 2026 net loss of $18.6 million (basic and diluted loss per share $(0.43)), slightly improved from $20.3 million a year earlier. R&D expenses rose to $31.0 million and SG&A to $150.7 million, reflecting expanded clinical programs and commercial investment. Cash, cash equivalents and marketable securities totaled $449.7 million as of June 30, 2026.
Tarsus completed the acquisition of iRenix Medical (IRX-101) and agreed to acquire Alkeus Pharmaceuticals and ALK-001, adding late-stage retina assets. It also priced a $125 million private placement financing and continues multiple Phase 2 and planned Phase 3 programs across ocular rosacea, Lyme disease prophylaxis and ocular antiseptics.
Tarsus Pharmaceuticals (Nasdaq:TARS) entered into a securities purchase agreement for an oversubscribed private investment in public equity (PIPE) expected to generate approximately $125.0 million in gross proceeds, before fees and expenses. The financing includes existing Alkeus Pharmaceuticals investors such as TCGX, Bain Capital Life Sciences, and Wellington Management, alongside new and existing Tarsus investors including ADAR1 Capital Management, Sirenia Capital Management, RTW Investments, and Vestal Point Capital.
Tarsus will sell 2,098,519 shares of common stock at $56.00 per share and pre-funded warrants to purchase 133,625 shares at $55.9999 per warrant, with an exercise price of $0.0001 per share. Closing is expected on August 7, 2026, subject to customary conditions. According to Tarsus, net proceeds will fund clinical development, commercial activities, and general corporate purposes. Barclays acts as lead placement agent, with BofA Securities and William Blair as co-placement agents.